ACXP could move through its Phase2b trial quickly, with enrollment already underway and the duration of treatment relatively short. In fact, treatment cycles can run as little as ten days, with follow-up done at 30 days. Thus, with ACXP powering through its Phase 2b trial supported with best-in-class data and an expected ticket to enter Phase 3, the ACXP investment proposition at current levels is frankly getting too big to ignore. Not only that, from an investors’ perspective, ACXP has never looked more ready to generate significant gains in the near term. Last Tuesday, Pfizer joined two other companies that showed less than impressive data from their C. In fact, all three had topline misses, which is often a death knell for a clinical trial. Further, all three appear to be scrambling to save its programs, knowing that the potential market in dollar terms to treat CDI is well worth the fight. Still, expect PFE, SNY, and SMMT to have uphill battles. But, bad news for them is excellent news for ACXP.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
August 2023
Categories |